Invesco Biotechnology & Genome ETF
PBE
94 hedge funds and large institutions have $70.3M invested in Invesco Biotechnology & Genome ETF in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
10% more capital invested
Capital invested by funds: $64M → $70.3M (+$6.3M)
7% more funds holding
Funds holding: 88 → 94 (+6)
0.95% more ownership
Funds ownership: 22.86% → 23.81% (+0.95%)
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.14M |
| 2 |
Morgan Stanley
New York
|
+$850K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$574K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$505K |
| 5 |
LPL Financial
San Diego,
California
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Avitas Wealth Management
Los Angeles,
California
|
-$405K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$295K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$277K |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$95.1K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
-$64.7K |
PBE Hedge Fund Activity: Q2 2021 in Review
94 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2021, worth a combined $70.3M — up 9.8% from $64M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PBE positions and 5 closed out — a net gain of 6 holders — while 15 added to existing stakes and 21 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.14M. The largest seller was Avitas Wealth Management, exiting entirely with an estimated $405K sold.
- 94 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2021, up from 88 in Q1 2021.
- Funds reported $70.3M of Invesco Biotechnology & Genome ETF stock for Q2 2021, up 9.8% quarter-over-quarter.
- 11 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2021 and 5 closed out, a net change of +6 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2021 was Susquehanna International Group, an estimated $1.14M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2021 was Avitas Wealth Management, an estimated $405K sold.
Based on aggregated 13F filings for Q2 2021.